EUVIMEDEUVIMED entdecken
Multizentrische Studie

Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry

Gloria Färber iD, Daniel Zimpfer, Jens Garbade, Jacob Lavee iD, Michiel Morshuis iD, Steven Shaw, Finn Gustafsson, Carlo Gazzola, AiJia Wang, Diyar Saeed iD, ELEVATE Investigators

European Journal of Cardio-Thoracic Surgery · 01.04.2026 · 68 (4)

DOI: 10.1093/ejcts/ezag106 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 23.03.2026. Verfasst von Gloria Färber und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, University Hospital Würzburg, Würzburg 97080, Germany. Hauptthemen laut MEDLINE: Heart-Assist Devices, Tricuspid Valve Insufficiency, Tricuspid Valve, Heart Failure. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Abbott.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess whether tricuspid valve surgery (TVS) during HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation affects long-term survival and outcomes.

Methods

The ELEVATE registry enrolled 540 HM3 patients across 26 centres; 463 undergoing primary LVAD implantation and at least mild tricuspid regurgitation (TR) formed this analysis. Concomitant TVS was performed in 70 (15.1%) patients. Five-year outcomes (survival, functional capacity, end-organ function, adverse events) were compared with those with similar severity of TR not receiving TVS in both overall population (with TVS n = 70 vs without TVS n = 264) and matched groups (each group n = 67, primary analysis cohort).

Results

In the matched cohort, baseline demographics of patients with or without TVS showed no differences in age (57.9 ± 10.8 vs 57.3 ± 10.0; P = .728), sex (male, 92.5% vs 94.0%; P = 1.000), preoperative short-term mechanical circulatory support rate (6.0% vs 9.0% P = .744), New York Heart Association (NYHA) class and quality of life (QoL) score, and end-organ function. Preoperatively, patients with TVS had shorter 6-minute walk distances (6MWD; 58.0 ± 109.0 m vs 105.3 ± 154.0 m; P = .081). At 5 years, patients with TVS showed no differences in survival (69.0% vs 59.3%, P = .67), 6MWD (311.1 ± 129.5 m vs 295.6 ± 137.7 m, P = .758), QoL score, or end-organ function while presented a lower risk of right heart failure (EPPY 0.038 vs 0.092, P = .03).

Conclusions

In the ELEVATE registry, concomitant TVS during HM3 implantation was not associated with differences in 5-year survival; however, it may have a positive effect on functional capacity and right heart function. Clinical registration number NCT02497950

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesTricuspid Valve InsufficiencyTricuspid ValveHeart FailureHumansFemaleMaleRegistriesMiddle AgedTreatment OutcomeAged

Stichwörter der Autor:innen

HeartMate 3concomitant valve surgeryheart failureleft ventricular assist devicetricuspid valve regurgitation

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, University Hospital Würzburg, Würzburg 97080, Germany.
  • Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Vienna 1090, Austria.
  • Department of Cardiothoracic Surgery, Klinikum Links der Weser, Bremen 28277, Germany.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.
  • Department of Cardiothoracic Surgery, Herz- und Diabeteszentrum NRW, Bad Oeynhausen 32545, Germany.
  • The Transplant Centre, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester M23 9LT, United Kingdom.

ORCID-Profile: Gloria Färber, Jacob Lavee, Michiel Morshuis, Diyar Saeed

Förderung

  • Abbott

Zitieren

APA

Färber, G., Zimpfer, D., Garbade, J., Lavee, J., Morshuis, M., Shaw, S., Gustafsson, F., Gazzola, C., Wang, A., Saeed, D., & ELEVATE Investigators (2026). Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry. European Journal of Cardio-Thoracic Surgery, 68(4). https://doi.org/10.1093/ejcts/ezag106

Vancouver

Färber G, Zimpfer D, Garbade J, Lavee J, Morshuis M, Shaw S, et al. Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry. European Journal of Cardio-Thoracic Surgery. 2026;68(4). doi:10.1093/ejcts/ezag106

BibTeX
@article{Frber2026,
  author = {Färber, Gloria and Zimpfer, Daniel and Garbade, Jens and Lavee, Jacob and Morshuis, Michiel and Shaw, Steven and Gustafsson, Finn and Gazzola, Carlo and Wang, AiJia and Saeed, Diyar and ELEVATE Investigators, ELEVATE Investigators},
  title = {Concomitant Tricuspid Valve Surgery During HeartMate 3 LVAD Implantation and Long-Term Outcomes: Insights From the ELEVATE Registry},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2026},
  volume = {68},
  number = {4},
  doi = {10.1093/ejcts/ezag106}
}
Kostenlos starten →